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Inherited bone marrow failure (BMF) syndromes comprise a heterogeneous group of 
genetic disorders characterized by dysfunction of hematopoietic stem cells. Studying the 
genetic lesions causing these diseases is critical for the development of better diagnostic 
tools, the understanding of underlying pathogenic pathways and the development of novel 
therapeutic strategies. In recent years, approximately 50 genes have been identified to be 
involved in pathogenesis of BMF syndromes. However, there are still many patients with 
BMF manifestations where the underlying gene mutation has not been identified.  
Myb-Like, SWIRM and MPN domains 1 (MYSM1) is a transcriptional regulator 
mediating histone deubiquitination. Its role in human immunity and hematopoiesis is 
poorly understood. Targeted deletion of murine Mysm1 results in severe hematopoietic 
defects associated with an early block of B cell development, defective stem cell-
maintenance, -self-renewal and -differentiation, as well as NK cell dysfunction. In 
humans, exome-sequencing studies have revealed potentially disease-causing mutations in 
MYSM1 in two families with BMF and immunodeficiencies. 
We comprehensively investigated the clinical, cellular and molecular features in two 
siblings presenting with progressive BMF, immunodeficiency and developmental 
aberrations. Genome-wide homozygosity mapping combined with whole-exome 
sequencing (WES) and Sanger sequencing revealed a premature stop codon mutation in 
MYSM1 (NM_001085487: c.1168G>T: p.E390*) resulting in absence of MYSM1 protein 
in patient cells. MYSM1-deficient cells are characterized by increased sensitivity to 
genotoxic stress associated with sustained induction of phosphorylated p38 protein, 
increased reactive oxygen species (ROS) production and decreased survival upon UV 
light-induced DNA damage. 
In summary MYSM1 deficiency is associated with developmental aberrations, progressive 
BMF with myelodysplastic features and increased susceptibility to genotoxic stress. 
HSCT represents a curative therapy for patients with MYSM1 deficiency. Our data further 
expand the spectrum of inherited human bone marrow failure disorders and highlight the 






4.1. Human hematopoiesis 
In a healthy human bone marrow (BM), approximately one trillion (1012) cells per day 
arise. This indicates that the blood system is one of the most highly regenerative tissues in 
our body. The presence of a regenerative cellular hierarchy system, later called 
hematopoietic stem cell (HSC), in BM was hypothesized in the early 20s by Maximow 
[1], but the first evidence of the existence of such a system came only during the second 
world war, when atomic bombs revealed the devastating effects of nuclear irradiation. 
After atomic violation in Japan, it has been discovered that the lethal consequence of 
radiation was due to BM and blood failure which was curable by injection of spleen or 
marrow cells of unirradiated donor [2]. By that time, it was still unclear whether there are 
multiple stem cells restricted to each blood cell lineage or all of the blood cells arise from 
a single multipotential HSC. A big move forward in understanding the hematopoietic 
system was achieved by Till and McCulloch in 1961. They could show that the 
regenerative potential of HSC can be tested with clonal in vivo repopulation assays [3]. 
Subsequently, other groups developed in vitro clonal expansions [4, 5].  
HSCs are defined by their special ability to durably self-renewal, while at the same time 
contribute to the pool of differentiating cells and are therefore critical for guaranteeing 
lifelong blood regeneration. Nowadays, surface markers are used to define HSCs as well 
as a variety of differentiated cell subtypes in bone marrow. CD34 (cluster of 
differentiation 34), which is expressed only on less than 5% of all nucleated bone marrow 
cells,  was the first marker found to enrich human HSCs and other blood progenitors [6]. 
CD34+ cells can also be found in cord blood (about 1%) and peripheral blood cells 
(<0.1%) [6, 7]. Further investigations identified other markers which could be used to 
either positively or negatively select human HSCs. Human HSCs are defined as CD34+ 
CD38- CD90+ (thymocyte differentiation antigen 1: Thy1) CD45RA- [8]. HSC first 
differentiate into cells called multipotent progenitors (MPPs) which lack self-renewal 
capability but are able to differentiate into all blood progenitors. In contrast to HSCs, 
human MPPs lack the expression of CD90 and CD49f. In addition, MPPs also differ from 
HSC in their epigenetic landscape. In HSCs the transcription factors (TFs) SOX8 (SRY-
related HMG-box 8), SOX18 and NFIB (nuclear factor I B) are upregulated. In contrast, 
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MYC (myelocytomatosis viral oncogene homolog) and IKZF1 (IKAROS family zinc 
finger 1) are upregulated during differentiation into MPPs [9]. Moreover, other TFs such 
as Polycomb-group gene BMI1 (B lymphoma Mo-MLV insertion region 1 homolog), 
HLF (hepatic leukemia factor) and HES1 (hairy and enhancer of split 1) are reported to be 
involved in HSCs quiescence [10, 11]. MPP cells can then differentiate into CMP 
(common myeloid progenitor) or MLP (monocyte-lymphoid progenitor) which can be 
distinguished by cell surface markers. CMPs are CD34+ CD38- CD45RA- CD10- CD7- 
while MLPs are known to be CD34+ CD38- CD45RA+ CD10+ CD7- [8]. CMPs give rise to 
MEPs (Megakaryocyte-Erythroid progenitor) which are able to fully differentiate into 
megakaryocytes and erythrocytes. Activation of PU.1 is required for differentiation of 
CMPs into GMP (granulocyte-macrophage progenitor) [12]. GMP cells which are 
CD45RA+ and CD135+ give rise to granulocytes, monocytes and dendritic cells.  
MLPs are responsible to generate B and T lymphocytes as well as NK cells. This process 
is orchestrated by  GATA2 (GATA binding protein 2), PU.1, NOTCH1 and PAX5 (paired 
box 5) [13]. 
The main TFs involved in human hematopoiesis, as well as surface markers are depicted 




Figure	  1:	  Schematic	  representation	  of	  human	  hematopoietic	  hierarchies.	  HSCs	  give	  rise	  to	  MPP	  which	  later	  differentiate	  to	  MLP	  and	  CMP.	  All	  
lymphoid	  cells,	  including	  B	  and	  T	  cells	  and	  NK	  cells,	  arise	  from	  MLP,	  while	  CMP	  fully	  differentiate	  into	  monocytes,	  granulocytes,	  erythrocytes	  




4.1.1. B cell development 
Development of B cells has been well dissected into several distinct stages based on cell 
surface markers and expression of TFs. In the initial step, E2A (E protein 2-alpha) and 
EBF (Early B cell factor) are critical TFs that specify B cell fates. B cell progenitors in 
this step, called Pre-pro-B cells, can be isolated from BM using CD34+ CD38+ CD10+ 
CD19- markers. Further development into pro-B cells is coupled with immunoglobulin-
gene (Ig) rearrangement events and expression of CD19 and CD24 markers. Pre-B cells 
start to express CD20 surface marker but became negative for CD34 stem cell marker. At 
the end of this step, VDJ (variable, diverse, joining) Ig rearrangement is completed and 
IgM (immunoglobulin M) can be expressed on cell surface. These cells are called 
immature B cells which are immunophenotypically defined as CD38+ CD10+ CD19+ IgM+ 
IgD- cells [13, 14]. Immature B cells exist in BM and are able to react to T cell–
independent type 1 antigens [15]. Immature B cells undergo negative selection in bone 
marrow in order to exclude strongly self-recognizing cells. Following negative selection, 
immature B cells leave the BM and proceed to further maturate in the spleen and other 
lymphoid organs [14]. Surface expression of IgD in addition to IgM is the hallmark of 
mature B cells. They are responsive to antigens and unless the cells encounter foreigner 
antigens, they die within a few weeks [16]. 





Figure	  2:	  B	  cell	  development	  in	  humans.	  Differentiation	  of	  CLP	  into	  the	  mature	  B	  cells	  occurs	  in	  the	  bone	  marrow.	  CLPs	  pass	  
through	  a	  CD34+CD19−CD10+	  early	  B,	  CD34+CD19+CD10+	  pro-­‐B,	  large	  CD34+CD19+CD10+	  pre-­‐BI,	  large	  CD34−CD19+CD10+	  pre-­‐
BII,	  small	  CD34−CD19+CD10+	  pre-­‐BII	  cell	  developmental	  pathway.	  Gene	  activation	  at	  each	  step	  has	  been	  characterized.	  This	  





4.1.2. Transcription factors and epigenetic regulation of B cell 
development 
During cellular differentiation, changes in gene expression as well as chromatin status 
occur, reflecting genetic and epigenetic regulation [18]. The transition process from HSCs 
to B cells is coupled with loss of self-renewal and multilineage potential. Once early B 
cell fate is established, a shift from low-level gene expression associated with HSCs to 
high expression level of lymphoid specific genes (such as Tdt and Rag1/2) occurs [19, 
20]. Activation of lymphoid specific genes is also accompanied by a sequential loss of 
megakaryocyte/erythroid and myeloid potentials [21, 22].  
TFs have been recognized as key regulators of hematopoiesis and their function ensures a 
precise and successful developmental transition from one stage of progenitor cell 
differentiation to the next. TFs function in a network or a cascade fashion rather than 
acting alone [23]. Activation of a fate specific TF leads to suppression of unwanted TFs of 
the alternate fates as well as activation of lineage-specific target genes [24]. 
One of the first TFs reported to be involved in lymphopoiesis was PU.1. PU.1 was 
originally identified as the target gene of proviral integration of the spleen focus forming 
virus (SFFV) in erythroleukemia [25]. PU.1 has a highly dynamic expression pattern that 
is restricted only to hematopoietic system. Using GFP (green fluorescent protein) reporter 
mice, it was shown that the expression of PU.1 is downregulated in HSCs and sequentially 
increasing along myeloid lineage (ST-HSCs > LMMP > GMP > macrophages and 
neutrophils) [12, 26]. Targeted disruption of Pu.1 in mice is fatal [27], while conditional 
deletion of Pu.1 in adult mice results in failure to generate CMPs and GMPs, indicating 
the necessity of this TF for specification of the myeloid lineage [28, 29]. Interestingly, De 
Koter et al. showed that enforced expression of Pu.1 in PU.1-deficient progenitors, drove 
lineage determination in a dose-dependent manner demonstrating that low versus high 
expression of PU.1 favors generation of B cells versus macrophages, respectively [30]. 
Their studies implied an essential role for PU.1 in generation of B cells, but only when 
expressed at reduced concentrations. It has been hypothesized that low expression of PU.1 
might prime modification of chromatin structure to facilitate transcription activation 
required for B cells development [31].  
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Figure	  3:	  Different	  faces	  of	  Pax5.	  Pax5	  expression	  has	  repression	  effect	  on	  T-­‐lymphoid	  and	  myeloid	  specific	  genes	  including	  
MPO,	   Notch1	   and	   M-­‐CSFR.	   Induction	   of	   B	   cell-­‐specific	   target	   genes	   by	   Pax5,	   such	   as	   CD19,	   Igα	   and	   Ig	   genes	   leads	   to	  
activation	  of	  BCR	  signaling	  pathways.	  The	  figure	  adapted	  from	  reference	  [32].	   
 
Another important player orchestrating CLP differentiation into B cells is PAX5. It has been 
shown that CLP (common lymphoid progenitors: CD34+ CD10+ CD19- CD7-) cells have 
upregulated expression of PAX5 [33]. This observation correlates well with findings in 
mouse, where CLPs already express different lymphoid-specific TFs including PAX5 [34]. 
Conditional ablation of Pax5 in CD19+ splenocytes results in loss of a B cell differentiation 
program and a striking conversion to T cell fate [35]. At the transcriptional level, PAX5 plays 
a dual role by repressing lineage-inappropriate genes and simultaneously activating B-cell-
speciﬁc genes (figure 3). Expression of at least 170 genes are regulated by PAX5 in which a 
signiﬁcant number of them are important for B-cell signaling, adhesion, and migration of 
mature B cells [36]. 
E2A, EBF and their target genes are still expressed in PAX5-/- pro-B cells, indicating that 
PAX5 functions downstream of E2A and EBF in controlling of B cell development (figure 4) 
[37, 38]. The E2A genetic locus encodes E12 and E27 by differential splicing events. These 
proteins are widely expressed and they all belong to the class I family of basic helix-loop-
helix (bHLH) proteins [39, 40]. Early studies on E2A-/- mice revealed B cell development 
arrest at the early pro-B cell stage, prior to the onset of Ig heavy chain rearrangement, 
demonstrating requirement for E2A activation at the earliest detectable stages of B cell 
commitment [41, 42]. Further investigation suggested that E2A is not only important for B 
lineage commitment, but also that it plays multiple roles at later stages of B cell maturation 
[43]. Ectopic expression of E2A in non-lymphoid cells activated B cell specific genes 
indicating the importance of E2A as a master regulator of B lymphopoiesis. For instance, in 
fibroblast cells, ectopic expression of E2A resulted in transcription of B cell-specific Ig heavy 
chain transcripts [44] and overexpression of E12 in a macrophage cell line also led to the 
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activation of a variety of B lineage genes, including the transcription factor EBF, the 
surrogate light chain lambda 5 and Rag-1 [45]. At later stages of B cell maturation, E2A acts 
to regulate class switching of immunoglobulin recombination in peripheral mature B cells 
[46].  
Like EBF-/- mice, E2A depletion results in a similar arrest of early B cell development [47]. 
The similarity of the B cell developmental arrest in E2A and EBF mutant mice strongly 
suggests a concerted action of these two TFs in controlling the earliest phase of B 
lymphopoiesis. Since pro-pre B cells in EBF-/- mice express almost normal level of E2A 
mRNA, whereas EBF transcription appear to be reduced in BM cells of E2A-/- mice, it has 
been concluded that E2A may act upstream of EBF in the genetic hierarchy of B cell 




Figure	   4:	   Transcription	   factors	   in	   B	   cell	   development.	   Sequential	   activation	   of	   four	   TFs	   involved	   in	   B	   cell	   development,	  
including	  PU.1,	  E2A,	  EBF	  and	  PAX5	  has	  been	  depicted.	  Figure	  adapted	  from	  reference	  [35]	  .	  	   
 
 
During B-cell development, besides the activation of the TFs, accessibility to the genomic 
region of the target genes is also required. This is achieved via epigenetic regulations and 
chromatin remodeling mechanisms. Murre et al. showed E2A occupancy near transcription 
start sites is associated with activating Histone H3K4 monomethylation marks (H3K4me1) at 
enhancers and H3K4 trimethylation marks (H3K4me3) at promoters. Moreover, E2A-
occupied sites co-localize with binding motifs of TFs essential to the B lineage fate including 
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EBF and PU.1 [49]. Following activation of other TFs, such as EBF, co-occupancy of these 
two TFs correlates with H3K4 methylation status and an abundance of the hallmark B lineage 
transcripts VpreB, Cd19, Foxo1, Pou2f1, Cd79a, and Pax5 [35]. These data prove that 
functional synergy between E2A and EBF at the epigenome level is critical for orchestrating 
B cell lineage-gene activation. In line with these data, genome-wide analyses demonstrated 
different sets of genes being activated or repressed by EBF TFs across defined stages of B cell 
development [50]. All EBF-activated target genes, including Cd79a and Pax5, gained the 
activating epigenetic marks H3K9me and H3ac (acetylated histone H3), whereas EBF-
repressed genes acquire repressive H3K27me3 marks. Another epigenetic regulation of B cell 
development was discovered by Busslinger et al. Their studies revealed that the Pax5 
enhancer is demethylated during HSC and MMP transitions, while it gains the active 
chromatin mark by the pro-B cell stage. Moreover, they could show that in the absence of 
E2A and EBF, the promoter region of Pax5 fails to acquire activating histone mark H3K9ac, 
demonstrating sequential and synchronized activation of TFs in B cell development [51].  
Other studies documented that the induction of CD19 expression in pro-B cells occurs upon 
acquisition of the H3K4me3 activating marks in the promoter regions and simultaneous 
activation of E2a, Ebf and Pax5 [52]. However, the effect of other histone modifications 
including ubiquitination and de-ubiquitination in B cells development remains elusive. 
In summary, B cell-lineage commitment and development is highly determined by activation 
of specific TFs, including PU.1 E2A EBF and PAX5, which leads to induction of B cell-
specific target genes and silencing of HSCs and the other lineage-specific genes through 
epigenetic regulation of regulatory elements (promoter, enhancer and silencer regions).  
 
4.2. Bone marrow failure syndromes; defect of hematopoiesis 
The inherited bone marrow failure syndromes (BMF) are characterized as a heterogeneous 
group of disorders representing bone marrow failure usually in association with one or more 
somatic abnormality. The failure in BM might affect either only a single or all three blood 
lineages and normally presents in early childhood. For instance, Fanconi anemia (FA) and 
dyskeratosis congenita (DC) usually affect all three blood lineages, whereas patients with 
Diamond–Blackfan anemia (DBA) initially present with single-lineage cytopenia affecting 
erythroid cells. Studying the genetic lesions causing these diseases is critical to better 
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understand underlying pathogenic pathways and to potentially define new therapeutic 
approaches.  
About 50 genes have been identified to be involved in pathogenesis of BMF syndromes [53, 
54]. Germline mutations in these genes results in the disruption of the key biological 
processes such as DNA repair and genome integrity (Fanconi anemia), telomere biology 
(Dyskeratosis congenital syndromes), or ribosomal biogenesis (Diamond Blackfan anemia, 
Shwachman Diamond syndrome) [55]. 
 
4.2.1. Fanconi anemia 
The Swiss pediatrician Dr. Guido Fanconi, first described a rare aplastic anemia disorder 
associated with growth anomalies, later called Fanconi anemia [56]. The disease is 
characterized as an inherited progressive BMF associated with congenital abnormalities and a 
pronounced susceptibility to malignancies [57].	  In approximately 60% of the reported cases of 
FA, at least one physical abnormality is documented. Among all the growth aberrations in FA, 
short stature as well as café au lait and hyper- and hypo-pigmented areas are the most 
common findings. The other reported abnormalities in FA are radial ray anomalies especially 
in thumb, microcephaly, microphthalmia, structural renal and endocrine anomalies [55].  
In the majority of cases, FA follows an autosomal recessive (AR) inheritance pattern, but 
some cases of X-linked inheritance have been reported as well (table 1). Hypersensitivity of 
the cells from FA patients to DNA cross-linking agents such as mitomycin C, which results in 
chromosomal breakage and genome instability, is the cytogenetic hallmark of this disease. 
The increased genome instability in FA is due to defective proteins involved in DNA repair 
mechanisms encoded by Fanconi anemia genes [58]. It has been discovered that at least eight 
of the Fanconi anemia proteins (FANCA, FANCB, FANCC, FANCE, FANCF, FANCG, 
FANCL and FANCM) interact with each other and form a nuclear complex called the 
“Fanconi anemia core complex”. This core complex is needed to activate the FANCI-
FANCD2 protein complex to a monoubiquitinated form (FANCI-FANCD2-Ub). FANCI-
FANCD2-Ub directly interacts with DNA repair proteins such as BRCA2, BRCA1, NBS1 
(Nijmegen breakage syndrome 1), PCNA (proliferating cell nuclear antigen) and RAD51, 
resulting in repair of damaged DNA. Of note, BRCA2 (also called FANCD1) is a human 
tumor suppressor gene critically involved in repair of DNA damage through homologous 
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recombination [55, 59]. FANCC also has been shown to be the co-interacting partner of 
BRCA2 [60, 61]. Certain variations in BRCA2 increase risks for breast cancer as part of a 
hereditary breast-ovarian cancer syndrome [62] while biallelic mutation in this gene cause FA 
(table 1) [53]. Patients with FA have an increased risk of developing Myelodysplastic 
syndrome (MDS) and leukemia [63]. In particular patients with mutation in FANCD1 
(BRCA2) have the highest risk for cancer with a cumulative probability of 97% by the age of 
6 years [55]. In regard to progressive bone marrow failure and increased risk of developing 
cancer in patients with FA, the life expectancy of FA patients is reduced to an average of 29 
years [55]. 
Despite significant recent advances in understanding the molecular function of FA proteins, it 
is still not fully understood why such a large multiprotein FA core complex is required for 
DNA repair.  
Table	  1:	  List	  of	  mutated	  Fanconi	  anemia	  genes.	  FA	  mutated	  genes	  as	  well	  as	  chromosomal	  location,	  inheritance	  pattern	  and	  
frequency	  of	  the	  mutations	  have	  been	  summarized.	  Data	  from	  reference	  [55].	  	  	  
 
Table	  1.	  List	  of	  mutated	  FA	  genes	  
Genes	  	   Chromosome	  locus	  	   Mode	  of	  inheritance	  	   Frequency	  (%	  of	  patients)	  
FANCA	   16q24.3	   AR	   60	  
FANCB	   Xp22.31	   XLR	   2	  
FANCC	  	   9q22.3	   AR	   14	  
FANCD1/BRCA2	   13q12.3	   AR	   3	  
FANCD2	   3p25.3	   AR	   3	  
FANCE	   6p21.3	   AR	   3	  
FANCF	   11p15	   AR	   2	  
FANCG/XRCC9	  	   9p13	   AR	   10	  
FANCI	   15q25–26	   AR	   1	  
FANCJ/BACH1/BRIP1	  	   17q22.3	   AR	   2	  
FANCL	   2p16.1	   AR	   0.2	  
FANCM	   14q21.3	   AR	   0.2	  
FANCN/PALB2	   16p12.1	   AR	   0.7	  
FANCO	   17q22	   AR	   1	  single	  case	  




4.2.2. Dyskeratosis congenita 
Dyskeratosis Congenita (DC) is characterized by skin pigmentation changes, leukoplakia, and 
nail dystrophy as well as BMF development in about 80% of cases by the age of 20 years 
[64]. The other less common physical aberrations in DC patients are constant tearing from 
lacrimal duct stenosis, sparse and/or early grey hair and eyebrows, poor dentition and 
developmental delay. Pulmonary and hepatic complications are also common. However, it has 
been noted that most of the physical findings in DC are age-dependent and thus absence of 
common symptoms in a young patient by no means eliminates DC from probable 
consideration [55]. Except for two very severe subtypes of DC (called Hoyeraal-Hreidarsoon 
syndrome and Revesz syndrome suffering from microcephaly, neurological findings, 
immunodeficiency and intrauterine growth retardation), DC is less severe compared to FA., 
The median age at diagnosis for DC is 14 years, which is more than double the age in FA 
[55]. 
The hallmark laboratory diagnostic test for DC is detection of very short telomeres (less than 
the 1st percentile for age in a large number of normal controls) in blood leukocyte subsets 
[65]. Telomeres are the end of linear chromosomes which are composed of tandem 
hexanucleotide (TTAGGG) repeats as well as associated proteins (figure 5). Telomeres get 
shorter with every cell division and genome replication. The telomerase enzyme, a 
ribonucleoprotein complex, elongates telomeres by adding telomeric repeats to the end of 
telomeres in early progenitor cells [66]. All seven DC genes encode proteins that are either 
part of the telomerase complex or associated telomere protein called shelterin complex. DKC1 
(dyskeratosis congenita 1, dyskerin) encodes a highly conserved nucleolar protein called 
dyskerin which plays an important role in telomerase function. DC can be inherited in an X-
linked pattern (mutation in DKC1) or in an autosomal recessive/dominant pattern. The other 
genes which have been discovered to be mutated in DC are TINF2 (TERF1 interacting 
nuclear factor 2), TERC (telomerase RNA component), TERT (telomerase reverse 
transcriptase), NOP10 (nucleolar Protein 10 also called NOLA3), NHP2 (ribonucleoprotein 
homolog 2 also called NOLA2) and TCAB1 (telomerase Cajal body protein 1 also called 
WRAP53). It has been shown that mutations in NOP10, NHP2 and TCAB1 cause autosomal 
recessive DC, but mutations in TERC, TERT and TINF2 can cause DC in both children and 
adults. Loss of function of only one alleil is sufficient to reduce telomerase activity and 





Figure	   5:	   Human	   telomere	   and	   telomerase	   complexes.	   Human	   telomerase	   consists	   of	   the	   large	   molecules;telomerase	  
reverse	   transcriptase	   (TERT)	   	   telomerase	   RNA	   (TR	   or	   TERC)	   and	   dyskerin	   (DKC1).	   The	   accessory	   compartments	   including	  
DNA	  helicase	  (RTEL),	  Shelterin	  and	  CST	  complexes	  coordinate	  telomerase	  function.	  This	  schematic	  figure	  has	  been	  adapted	  
from	  reference	  [67]. 
 
 
4.2.3. Diamond–Blackfan anemia 
Diamond–blackfan anemia (DBA) usually presents in early infancy and is characterized by 
selective red cell aplasia associated with a variable number of somatic abnormalities. The 
most common growth aberrations are craniofacial, thumb abnormalities, cardiac and 
urogenital malformation [68]. In a few patients with DBA, MDS and acute leukemia have 
been reported, which suggests an increased susceptibility to hematologic malignancies [53]. 
The median age of diagnosis and the median overall survival of the patients are about 3 
months and 40 years, respectively. Unlike FA and DC, there is not a clear-cut diagnostic 
method for DBA, however in blood counts of suspected cases, macrocytic anemia with 
reticulocytopenia, often with increased Hb F, as well as elevated red cell adenosine deaminase 
can be indicative of DBA. Erythroblastopenia with normal or reduced cellularity of BM is 
documented in BM evaluations of DBA patients [55]. 
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DBA was the first human disease described to be directly linked to defective ribosome 
biogenesis. However, there was an initial incredulity that an erythropoiesis deficiency may be 
caused by a defect in a housekeeping pathway essential for every dividing cell. RPS19 
(ribosomal protein S19) was the first gene identified to be mutated in DBA [69]. Later several 
heterozygous mutations in other genes encoding for ribosomal proteins of the small (RPS24, 
RPS17, RPS7, RPS10, RPS26) and large (RPL5, RPL11, RPL35A) ribosomal subunits have 
also been documented to be causative of BDA [53]. To date however, approximately half of 
all DBA cases lack identifiable genetic alterations. The inheritance pattern of DBA is 
autosomal dominant with some ethnic differences in phenotypic expression [53]. 
Haploinsufficiency in ribosome biogenesis is thought to be the responsible mechanism for 
DBA [70]. 
 
4.2.4. Shwachman–Diamond syndrome 
Shwachman–Diamond syndrome (SDS, also known as Shwachman-Bodian-Diamond 
syndrome) is an AR disorder characterized by BMF, pancreatic insufficiency associated with 
somatic abnormalities, in particular short stature and metaphyseal dysostosis [55, 71]. Signs 
of malabsorption and pancreatic insufficiency are apparent early in infancy (the median age of 
diagnosis is about 2 weeks). Neutropenia is the most common presenting hematological 
abnormality in SDS (~20%). Evolution of MDS and leukemia are observed in SDS patients as 
well [53].  
In more than 90% of SDS cases, biallelic mutation in SBDS (Shwachman-Bodian-Diamond 
Syndrome) is causative of the disease. SBDS is a highly conserved protein, shuttles in and out 
of nucleolus. In mammals, SBDS can bind to 60S large ribosomal subunit and is involved in 
ribosome maturation and mitotic spindle stabilization [55]. Studies of bone marrow cells of 
SDS patients revealed that hematopoietic cells of the patients exhibit cell intrinsic defect in 
proliferation and differentiation [72] which was also confirmed in Sbds knockdown mice [73]. 
The studies demonstrated hypersensitivity to multiple types of DNA damage as well as 
endoplasmic reticulum stress in SBDS-deficient cells [74]. Moreover, SDS marrow stromal 
cells exhibit an impaired ability to support hematopoiesis of progenitor cells from healthy 
donors [72]. Abnormal B and T cell numbers and function as well as F-actin 




4.2.5. Severe congenital neutropenia 
Severe congenital neutropenia (SCN) was first described by Rolf  Kostmann in 1950 as a 
disease affecting maturation of neutrophil granulocytes [77]. Classical definition for SCN is 
an absolute neutrophil count of less than 500 per microliter, associated with invasive bacterial 
infections such as omphalitis, skin abscesses, pneumonia, or septicemia [78]. Typically, SCN 
is not associated with any physical abnormalities in childhood, but in some patients decreased 
bone mineral density, leading to osteopenia or osteoporosis and increased propensity to 
fracture, is a common clinical problem [78]. BM examination in patients suffering from SCN 
shows an arrest in neutrophil maturation at the promyelocyte/myelocyte stage (figure 6), 
however cellularity of BM is normal or slightly reduced, and other cell lineages have normal 
maturation [55].  
SCN can be distinguished from cyclic neutropenia through sequential assessment of 
neutrophil counts over a 6 week period, equivalent to two 21 cycles [55].  
Due to the lack of comprehensive epidemiological studies, evaluation of SCN prevalence is 
difficult. Recent surveys in Iranian, French and some other ethnicities revealed that the 
minimal prevalence of congenital neutropenia appears to be 6 cases per one million [79]. SCN 
is most frequently caused by dominant mutations in the neutrophil elastase gene (ELANE) 
[80]. However, the original SCN disease which was first described by Kostmann appeared to 
be due to AR mutations in HAX1 (HS1-Associating Protein X-1) [81]. Recent studies revealed 
new genetic mutations causing SCN, including G6PC3 (glucose phosphatase catalytic subunit 
3), GFI1 (growth factor independence 1), WAS (Wiskott–Aldrich syndrome; causing X-linked 
SCN), JAGN1 (jagunal homolog 1), GCSF3R (granulocyte colony-stimulating factor 3 
receptor) and VPS45 (vacuolar protein sorting 45 homolog) [82-87]. Nevertheless, the genetic 
cause of many SCN cases remains elusive [78]. 
 Hematopoietic stem cell transplantation (HSCT) is the only definitive cure for SCN patients. 
First line therapy is based on administration of recombinant G-CSF (Granulocyte-colony 
stimulating factor). Patients who are non-responders or who develop MDS/AML after G-CSF 






4.2.6. Other less common BMF syndromes 
There are other BMF syndromes, including amegakaryocytic thrombocytopenia (CAMT), 
thrombocytopenia absent radii (TAR), radioulnar synostosis (RUS) and Pearson syndrome 
(PS), that are not as prevalent as the syndromes previously described. CAMT presents usually 
with petechiae or hemorrhages and sometimes evolves into aplastic anemia. Blood counts 
show thrombocytopenia with or without pancytopenia. Cellularity of BM may be normal, but 
decreased numbers or complete absence of megakaryocytes is evident. All CAMT patients 
carry AR mutation in MPL (myeloproliferative leukemia virus oncogene), which encodes the 
receptor for thrombopoietin. The only curative therapy for CAMT patients is HSCT [55]. 
Thrombocytopenia at birth associated with physical abnormalities of bilateral absent radii has 
been reported in patients suffering from TAR. The presence of thumbs makes these patients 
distinguishable from FA, however, chromosomal breakage test helps to better differentiate FA 
from TAR. The bone marrow of the patients with TAR shows reduced numbers or lack of 
megakaryocytes while the other lineages are normal. Genetic studies have failed to define a 
consistent finding in all 100 reported cases of therefore and the causative gene(s) remains 
elusive [55, 88]. 
Autosomal dominant mutations in HOXA11 (homeo box A11) have been reported in two 
patients with RUS which is characterized with thrombocytopenia or aplastic anemia, and 
patients are noted to have limited pronation/supination of the arms due to proximal radioulnar 
synostosis [55]. 
Myeloblast Promyelocyte Myelocyte Metamyelocyte Neutrophil 
Figure	  6:	  Myeloid	  maturation	  arrest.	  Bone	  marrow	  smears	  in	  patients	  suffering	  from	  SCN,	  typically	  reveal	  a	  severe	  paucity	  of	  mature	  neutrophils.	  
Since	  the	  arrest	  occurs	  normally	  after	  promyelocyte,	  myeloblasts	  and	  promyelocytes	  are	  present	  and	  detectable. 
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Pearson syndrome is characterized by malabsorption, refractory sideroblastic anemia/aplastic 
anemia and lactic acidosis. BM cellularity in PS patients, in contrast to SDS, is normal but 
cytoplasmic vacuoles in myeloid and erythroid precursors and ringed sideroblasts can be 
noted. The disease shows maternal inheritance pattern and all the patients carrying mutations 
in mitochondrial genes involved in respiratory chain function [89].   
Despite recent advances in genetic etiology of BMF syndromes, there are still many patients 
that exhibit features consistent with an inherited BMF syndrome however the causative gene 
mutation remains unknown and required further investigations [54]. 
 
 
4.3. Histone H2A ubiquitination and de-ubiquitination 
Histones are subject to the various types of modifications, modulating chromatin accessibility 
during gene transcription, DNA repair and chromosome condensation. Methylation, 
acetylation, phosphorylation, ubiquitination and sumoylation are the most common post-
translational modifications of histones [90]. Histone H2A was the first protein shown to be 
ubiquitinated (Ub) [91], and the site of modification was demonstrated to be in the highly 
conserved C-terminal containing Lys 119 residue [91, 92]. Approximately 5-10% of the total 
H2A present in mammalian cells are mono-ubiquitinated. [93] mono-Ub correlates with gene 
silencing pattern [94-96]. A growing body of evidence supports an additional critical role for 
Ub-H2A in the maintenance of genome integrity and stability [97].  
Ubiquitin is a polypeptide composed of 76 amino acids that is covalently attached to histone 
lysines via the sequential action of three enzymes, E1-activating, E2-conjugating and E3-
ligating enzymes. This large enzyme complex determines both substrate specificity (meaning 
which lysine is targeted) and the degree of ubiquitination (mono or poly-Ub) [98]. The major 
E3 ligase that mediates H2A mono-Ub is RING1b. RING1a/b- BMI1 (also called RNF2; Ring 
Finger Protein 2) is a component of the PRC (Polycomb repressive complex) that mediates 
silencing of the genes via histone modifications and chromatin remodeling [94].  
Analysis of global Ub-H2A levels during cell cycle showed that Ub of H2A is very dynamic 
[99, 100]. Several mammalian H2A deubiquitinating enzymes (DUBs) have been identified. 
Based on homology of catalytic domains of DUBs, five different families, including 
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Otubain/Ovarian tumor-domain containing proteins (OTU), ubiquitin carboxy-terminal 
hydrolases (UCH), ubiquitin specific proteases (Usp), Machado-Joseph Domain (Josephin 
domain)-containing proteins (MJD) and Jab1/MPN domain associated metalloprotease 
domain proteins (JAMM) have been described [101]. Among the DUBs, only the JAMM 
family utilizes a zinc metalloproteinase domain to break the bond between target proteins and 
Ub. Nine different DUBs have been classified in the JAMM family including PSMD7 
(proteasome 26S subunit, non-ATPase 7), PSMD14 (proteasome 26S subunit, non-ATPase 
14), EIF3H (eukaryotic translation initiation factor 3 subunit H), BRCC36 (BRCA1/BRCA2-
containing complex subunit 3), AMSH	  (associated molecule with the SH3 domain), AMSH-
LP (AMSH-like protein), MPND (MPN domain containing), PRPF8 (pre-mRNA processing 
factor 8), and MYSM1 (Myb-like, SWIRM and MPN domains 1) [102].  
USP16, USP3, and MYSM1 specifically deubiquitinate histone proteins [99]. Disruption of 
USP3 and USP16 leads to aberrant cell cycle progression and delayed S-phase [103].  
 
4.3.1. MYSM1 
MYSM1 was originally discovered in research attempts screening for potential transcription 
coregulators of androgen receptor-dependent gene activation [104]. MYSM1 is the only DUB 
enzyme which contains a SANT (switching-defective protein 3, adaptor 2, nuclear receptor 
corepressor, and transcription factor IIIB) DNA binding domain, that enables it to directly 
interact with double strand DNA (figure 7).  
	  
Figure	   7:	   Domain	   structure	   of	   JAMM/MPN+	  DUBs.	   SANT	   domain	   and	   SWIRM	  domain	   of	  MYSM1	   is	   quite	   unique	   among	  




The human MYSM1 protein, previously called 2A-DUB or KIAA1915, is encoded by 
MYSM1 (ENSG00000162601) mapped on chromosome 1 (1p32.1). MYSM1 is composed of 
828 amino acids (aa) forming three main structural domains including a SANT domain (aa 
116-167); SWIRM domain (aa 372-470) and a MPN domain (aa 572-682). The SANT 
domain is a well-known domain existing in many transcriptional regulators and is capable of 
binding directly to DNA and histones. SWIRM which is named for its presence in the proteins 
Swi3, Rsc8, and Moira exists in many chromatin associated proteins interacting with histones. 
The MPN domain is the metalloprotease catalytic site of MYSM1. The JAMM motif (aa 656-
669) is located at the end of the MPN domain and is followed by a generic LXXLL motif, 
found in many coactivators for interaction with agonist-bound nuclear receptors. The 
complete X-ray crystallographic structure of MYSM1 remains to be solved, but the 3D 
structure of SANT and SWIRM domains have been studied (figure 8). 
MYSM1 can be post-translationally phosphorylated at aa residues 110, 208, 236, 242, 267, 
and 340 [104]. 
 
	  
Figure	  8:	  Schematic	  illustration	  of	  MYSM1	  protein 
 
Early investigations documented that MYSM1 coordinates de-ubiquitination of H2A which 
subsequently results in acetylation of nucleosome histones and disassociation of histone H1 
[104]. It has been proposed by Zhu et al. that MYSM1 acts as a coactivator of androgen 
receptor-gene activation and is required for the activation of several target genes in prostate 
cancer cell lines [104]. 
Homozygous Mysm1-/- mice are viable and fertile. They have truncated tails, growth 
retardation, and reduced numbers of B220+ CD19+ B cells in bone marrow, spleen, and lymph 
nodes [106]. In addition to the striking defect in B cell differentiation, other groups later 
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reported bone marrow failure, lymphopenia, anemia, and thrombocytosis in Mysm1-/-  mice 
[106-108]. In the study performed by Nijnik et al., Mysm1-/- mice showed more severe 
phenotypes including increased levels of embryonic mortality, reduced body size and weight, 
and some growth abnormalities. In bone marrow of the Mysm1-/- mice, functionally impaired 
HSCs was reported to be associated with elevated DNA damage marker and increased 
reactive oxygen species (ROS) production. This study highlighted a critical role for MYSM1 
in maintenance of BM stem cell, lymphocyte development and genome stability [107].  
Bone marrow failure, HSC dysfunction in maintenance and self-renewal as well as defective 
hematopoiesis in Mysm1-/- mice has also been documented by other groups [109-111]. Further 
investigations have revealed that mice lacking MYSM1 represent defective NK maturation 
and dendritic cells development as well as problems in skin pigmentation and bone formation 
[110, 112-114]. 
During the course of our investigations, which started in 2011, three patients with 
homozygous mutations in MYSM1 suffering from bone marrow failure, anemia and 
lymphopenia associated with mild growth aberrations have been reported [115, 116].  
 
4.3.2. MYSM1 in hematopoiesis 
HSC dysfunction and defective hematopoiesis, mainly in B cells, were the most prominent 
finding of the initial Mysm1-/- mice studies that led investigators to search for a transcriptional 
regulatory function for MYSM1 in hematopoiesis.  
The fact that the B cell developmental block caused by MYSM1 loss occurred at a similar 
stage (pre-pro-B cell) that had been described for the Ebf1-/- mice, led the investigators to 
connect Mysm1 and Ebf1 functionally. Indeed, MYSM1 regulates EBF1 transcription in early 
B cell commitment by controlling histone modifications and TF recruitment at the Ebf1 
promoter locus [106].  
Further studies revealed that MYSM1, in coordinated action with GATA2 and RUNX1, 
regulates expression of GFI1. Reduced binding of GATA2 and RUNX1 TFs to the GFI1 
locus and increased recruitment of Ring1B and Bmi1 (components of PCR1) have been 
associated with loss of MYSM1 [109].  
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The importance of MYSM1 in the development of dendritic cells was studied by Won et al. 
They showed that MYSM1 is selectively required for Flt3L-induced DC development and 
upregulates expression of Flt3 through direct binding at the promoter locus [110].  
It has been hypothesized that depletion of HSC and impaired hematopoiesis in Mysm1-/- mice 
likely results from activation of the DNA damage response (DDR) and uncontrolled 
production of ROS [117]. The same functions, such as regulation of HSC quiescence and self-
renewal, antioxidant and DNA repair functions, as well as HSC differentiation checkpoints 
have been demonstrated for p53 [118-120]. Therefore, a possible connection between Mysm1 
and p53 was studied by two independent groups, which brought new insights into the 
molecular biology of MYSM1. Growth retardation and neurological abnormalities as well as 
defective lymphopoiesis of Mysm1-/- mice could be almost fully rescued by deletion of p53 
[117, 121]. Mechanistically, it has been shown that Mysm1 has the potential to directly bind 
to the prompter region of Cdkn2a/p19ARF, one of the major regulator of p53, and suppresses 
activation of p53 [117]. Colocalization of MYSM1 and p53 on the promoters of the classical 
p53-target genes Bbc3 (BCL2 binding component 3 also known as PUMA (p53 upregulated 
modulator of apoptosis)) and Cdkn1a/p21 has also been reported, suggesting a critical 
functional relationship between MYSM1 and p53 [122].  
The findings derived from Mysm1-/- and p53-/- mice strongly suggest that molecular 
mechanism of BMF and defective hematopoiesis in MYSM1 deficiency is p53 mediated and 
indicates the importance of MYSM1 in DNA damage and apoptosis protection. However, the 
exact molecular mechanism of MYSM1 function in DNA damage response in human is still 
unknown (see manuscript #1) 
 
 
4.4. SMARCD2-deficiency; role of chromatin remodeling 
complex in hematopoiesis and neutropenia 
The human genome is organized into chromosome structures composed of DNA, packaging 
proteins (primarily histones), factors for histone deposition and removal, histone modiﬁcation 
enzymes and a set of chromatin remodeling complexes (CRCs). The chromatin remodelers 
work in concert with other chromatin factors to control packaging and unpackaging of DNA 
and regulate DNA replication, gene transcription, DNA repair and recombination [123]. Four 
31	  
	  
different families of CRCs have been described, including SWI/SNF (switching 
defective/sucrose nonfermenting), ISWI (imitation switch), CHD (chromodomain, helicase, 
DNA binding) and INO80 (inositol requiring 80) family (figure 9). 
 
	  
Figure	  9:	  The	  families	  of	  chromatin	  remodeling	  complexes.	  Figure	  adapted	  from	  reference	  [123]. 
 
 
In mammals, two SWI/SNF multiprotein complexes have been described, called BAF (BRG1-
accosiated factor) and PBAF (polybromo-BRG1-associated factors). The complexes share 
multiple proteins, such as BAF170, BAF155, BAF60a/b/c, BAF57, BAF53a/b, BAF47, 
BAF45a/b/c/d and β-actin. The main difference between the BAF and PBAF complexes is the 
ATPase subunit. In BAF, the ATPase subunit can be either BRG1 or BRM, whereas in PBAF 
it is only BRG1 [123, 124]. The role of the SWI/SNF remodeler family in embryonic 
differentiation and organs development as well as in DNA damage response, genome 
stability, cancer and tumorigenesis have been studied extensively [124, 125]. 
One of the core components of the BAF remodeler complex is a 60 kDa subunit called 
BAF60 that can be represented by the paralogous proteins BAF60a, BAF60b or BAF60c, 
encoded by the SMARCD1, SMARCD2 and SMARCD3 genes, respectively [126]. It has been 
documented that BAF60c is essential to activate both skeletal and cardiac muscle programs. 
BAF60c deficiency in mice leads to severe cardiac defects and in zebrafish causes heart 
developmental deficiencies [127, 128]. Studies have revealed that BAF60a has a pleiotropic 
role in cells, varying from regulation of metabolic gene programs in the liver and skeletal 
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muscles to association with lung cancer risk, binding to p53 and steroid receptor function 
[129-131].  
SGD (neutrophil-specific granule deficiency) is a rare inherited disorder characterized by 
frequent and severe bacterial infections, lack of secondary granule proteins and defensins as 
well as neutrophils dysfunction and impaired bactericidal activity. SGD is caused by biallelic 
mutations in C/EBPε (CCAAT/enhancer binding protein E) [132]. However, there are very 
rare cases associated with specific granule deficiency who have no mutations in CEBPE.  
C/EBPs are a family of TFs involved in cellular differentiation and function in a variety of 
tissues [133]. At least six different members of this family (C/EBPα—C/EBPζ ) have been 
isolated and characterized [134]. C/EBPε is a 281 aa protein, exclusively expressed in 
myeloid cells and T cell lineages [135, 136]. Mice lacking C/EBPε show a similar phenotype 
seen in patients with CEBPE-deficiency [137].  








































































































9.1.1. Identification of premature stop codon mutation in MYSM1 
and its clinical relevance. 
In our study, we used the power of whole exome sequencing to identify the underlying 
genetic defect in two patients with an unusual presentation of bone marrow failure. The 
mutation in MYSM1 (NM_001085487: c.1168G>T) results in a premature stop codon 
mutation in aa 390 (p.E390*). Detailed, genetic, clinical, and immunological findings for the 
individual patients are provided in the manuscript #1. MYSM1-deficient patients share 
several phenotypic aspects with Mysm1-/- mice, including BMF, severe B cell deficiency, 
anemia and neutropenia [106, 107, 115, 138]. These data support and build upon previous 
findings regarding the importance of MYSM1 in hematopoiesis, notably in B cell 
development. It is possible that the hematopoiesis defect, in particular the B deficiency, 
observed in MYSM1-deficient patients results from a transcriptional deregulation of key 
factors involved in hematopoiesis and B-cell development, as found in Mysm1-/- mice [107-
109, 139]. However, investigations on transcription regulation in bone marrow cells of our 
patients were not feasible due to the lack of HSCs in bone marrow of the patients 
In contrast to the other reported MYSM1-deficient patient, who showed reduced number of 
CD3+, CD4+ and CD8+ cells in periphery [116], we did not observe any consistent T cell 
phenotype in our patients. However, the clinical need to undergo allogeneic HSC 
transplantation prevented us from performing extensive T cell studies. In depth analysis of 
human T cell differentiation and function will be needed in the future, when additional 
patients with MYSM1 deficiency will be identified. 
Dysplastic findings of red and white blood precursors are quite common in BMF syndromes 
such as FA, DBA, SDS, and SCN. Cytogenic investigations on BM specimens of our patients 
revealed MDS findings including Pseudo Pelger-Huet anomaly as well as multinucleated 
erythroblasts, cytoplasmic bridges and ectopic nuclear morphology of erythroblast 
(Manuscript #1). Dysplastic findings of erythroid and megakaryocytes had been also noted in 
the first reported MYSM1-deficient patient [115]. Indeed, lack of MYSM1 function is 
correlated to dysplastic features of blood cells precursor cells. Thus, studying the role of 
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MYSM1 may help to unravel molecular mechanisms preventing dysplasia of blood cells in 
healthy individuals. It remains currently unknown whether dysplasia in MYSM1-deficiency is 
associated with clonal aberrations. Further studies with gene marked human hematopoietic 
stem cells transplanted in immunodeficient mice will help to address this important question 
in the future.  
Studies of Mysm1-/- mice disclosed that Myms1 function is not restricted to BM and B cells, 
but may also affects other immune and nonimmune cells [110, 112, 113]. Our patients had 
growth retardation and mild neurocognitive impairment, possibly related to MYSM1 
deficiency. It is however not easy to differentiate these potentially MYSM1-related effects 
from other genetic factors in highly consanguineous pedigrees.  
Our investigations were of relevance to the clinical management and thus are an example of 
how molecular studies in patients with rare diseases can be directly helpful for the therapy of 
individual patients. In view of the progressive bone marrow failure and cellular 
immunodeficiency, both patients received transplantation of HLA matched healthy 
hematopoietic stem cells. Conditioning regimens vary a lot and should be adapted to the 
underlying disease. For example, patients with defects in genomic integrity (i.e. Fanconi 
anemia) require less intensive conditioning and avoidance of irradiation. Patients with auto-
inflammatory disorders such as IL10R deficiency need intensive immunosuppression [140]. 
The fact that we could show increased stress responses and delayed re-equilibration of cellular 
homeostasis in MYSM1 deficient cells led us to choose a targeted conditioning approach 
using reduced intensity conditioning (fludarabine (150mg/m²), treosulfan (42g/m²), 
alemtuzumab (0,4mg/kg)). Of note, the success of this approach also documents that the bone 
marrow stromal cells appear not to be affected in MYSM1 deficiency. As expected, the 
neurological anomalies could not be cured by re-establishing a healthy hematopoietic system.  
 
9.1.2. Increased stress response in MYSM1-deficient patient cells 
Following DNA damage, ubiquitination of H2A at ɣ-H2AX containing foci resulting in 
activation of cellular repair mechanisms has been shown previously [141, 142]. The role of 
DUB enzymes in regulation of DNA damage response (DDR) has been studied by different 
groups. USP3 and USP6 deficiencies have been associated with accumulation of spontaneous 
DNA damages and stable and silencing of the genes near DNA-damaged sites [103, 143, 
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144]. The role of the other de-ubiquitination enzymes, such as MYSM1, in DDR is largely 
unknown. Studying spontaneous and induced DNA damage in MYSM1-deficient cells 
provided us an opportunity to shed light on the role of DUBs in DDR and genome stability.  
Elevation of ɣ-H2AX has been documented in HSCs and blood progenitors of Mysm1-/- mice 
[107]. In accordance with these findings in mice, the cells from MYSM1-deficient patients 
also were characterized by elevated levels of ɣ-H2AX, reflecting increased genome 
instability. Moreover, increased levels of ɣ-H2AX were detected in patient cells following 
genotoxic stress induction such as UV light. These data are in line with the findings of Nishi 
et al. showing MYSM1 is recruited to the site of DNA damage and is involved in cell cycle 
checkpoint regulation [145]. However, due to the lack of suitable MYSM1 antibody for 
immunofluorescence studies, we were not able to study co-localization of MYSM1 and ɣ-
H2AX in primary patient cells. Further investigations are required to define the molecular 
mechanism of elevated DNA instability in MYMS1-deficient mice and human cells.  
Following genotoxic stress induction in MYSM1-deficient patient cells, increased rate of 
apoptosis, elevation of ROS production, cell cycle arrest and increased genome instability 
were observed, which demonstrate that MYSM1 is involved also in cell survival, genome 
repair and cell cycle progression.  
Mysm1 may be linked to the tumor suppressor protein p53. Two independent groups 
generated Mysm1-/- p53-/- double-deficient mice that showed almost complete recovery of 
hematopoietic defects observed in Mysm1-/- mice [117, 121]. Furthermore, co-localization of 
p53 and Mysm1 in p53 correlated genes, such as Bbc3/PUMA and Cdkn1a/p21, has been 
documented by Belle et al [122]. The established link between MYSM1 and p53 may be 
helpful with respect to the identification of pharmacological compounds.  
Cross-activation of p53 and p38 has been shown to play a key role in genotoxic stress 
responses [146-149]. In order to analyze p53 and p38 activation in MYSM1-deficient cells, 
we studied p38 activation and p38-mediated stress responses in fibroblast cells of our patient. 
This analysis suggested that MYSM1 is involved in fine-tuning stress response equilibration, 
as MYSM1-deficient cells showed sustained induction of Phosphorylated-p38 (P-p38). Our 
reconstitution data unequivocally prove that the increased susceptibility to genotoxic stress is 
caused by MYSM1 deficiency. Further investigations are required to define p38 p53 
interaction and the mechanism of p38 regulation by MYSM1. Based on our findings and the 
published data about MYSM1, we propose that MYSM1 regulates hematopoiesis, B cell 
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development and genotoxic responses through controlling of histone de-ubiquitination and 
regulation of transcription (Figure 10) 
Taken together our study on MYSM1-deficient patient cells showed that lack of MYSM1 
leads to the hypersensitivity of cells to genotoxicity which indicates MYSM1 plays an 
essential role in stress-induced responses and cell survival.  
 
	  
Figure	  10:	  MYSM1-­‐deficiency	  in	  human	  leads	  to	  immunodeficiency,	  developmental	  aberrations	  and	  BMF.	  In	  wild	  type	  cells	  
MYSM1	  properly	  regulates	  de-­‐ubiquitination	  of	  H2A	  and	  transcription	  repression.	  De-­‐ubiquitination	  of	  H2A	  and	  transcription	  
repression	   of	   p53	   and	   its	   target	   genes	   are	   impaired	   in	   MYSM1-­‐deficient	   cells	   leading	   to	   elevation	   of	   ROS,	   apoptosis,	  
sustained	  induction	  of	  p38	  and	  cell	  cycle	  arrest,	  consequently	  resulting	  in	  developmental	  aberrations,	  immunodeficiency	  and	  
BMF.	  The	  figure	  is	  taken	  from	  http://dx.doi.org/10.1016/j.jaci.2016.10.053 
 
 
9.1.3. Chromatic remodeling complex can cause SGD and 
neutropenia 
 
Previously it has been shown that rare mutation in CEBPE can cause SGD, elucidating the 
importance of CRCs for hematopoiesis and neutrophil maturation [132]. Our group has 
identified a new genetic defect associated with specific granule deficiency in 3 unrelated 
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families (Manuscript #2, Nature Genetics, in press). Using homozygosity mapping and NGS 
we discovered mutations in SMARCD2, an integral member of the SWI/SNF complex, 
known to control nucleosome positioning and chromatin reassembly. 
Our biochemical studies could document SMARCD2 interacts with CEBPE, disclosing a 
direct functional correlation of SMARCD2 and CEBPE. SMARCD2 appears to bring CEPBE 
to relevant promotor sites, thus orchestrating the transcription of CEBPE-dependent genes in 
neutrophil granulocytes. However, the phenotype of SMRACD2 deficiency does not 
completely match the phenotype of CEBPE deficiency which is limited to anomalies of 
neutrophil granulocytes. SMARCD2 also affects hematopoietic stem cells (where it acts as 
transcriptional repressor, in contrast to its role as transcriptional activator in more mature 
precursor cells of neutrophil granulocytes) and non-hematopoietic systems such as bones.  
We tried to establish a SMARCD2-deficient myeloid cell using CRISP/Cas9 mediated gene 
editing. However, our attempts failed probably due to the toxicity of SMARCD2 loss in cell 
lines. Only SMARCD2 knockdowns (using shRNA) gave rise to viable derivative clones. 
Further investigations are required to characterize SMARCD2 function in cell survival and 
development. Similar to patients with MYSM1 deficiency, patients with SMACD2 deficiency 
showed signs of myelodysplasia. The clinical picture thus highlights a critical role of 
chromatin remodeling/epigenetic control in both monogenic diseases. 
 
  
9.1.4. Outlook – Basic lessons in biology from studying inherited 
rare diseases of the immune system 
Inherited BMF syndromes comprise a heterogeneous group of deficiencies characterized by 
hematopoietic stem cell defects, with or without affecting other organ systems. This work 
extends the spectrum of known BMF disorders and highlights novel principles governing 
hematopoietic stem cell renewal and differentiation.  
Investigations of FA eventuated in a better understanding of genome integrity and DNA repair 
mechanisms. Molecular inspections revealed interaction of FA proteins with proteins involved 
in other rare genetic chromosome instability syndromes such as ATM (ataxia-telangiectasia 
mutated), MRE11 (MRE11 meiotic recombination 11 homolog) and ATR (ATM and Rad3-
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related), which play essential roles in DNA damage response and the pathogenesis of genome 
instable disorders [150]. Further investigations of FA associated genes linked them to cancer 
pathogenesis and disclosed that acquired mutations in FA genes presents in a wide variety of 
human cancers [151-154].  
Telomere biology was first linked to medicine by the discovery of telomerase genes mutants 
in DC. BM and skin which have a high cell turnover are the most affected tissues in DC. 
Critically, shortened telomeres subsequently lead to activation of DNA damage machinery, 
cell cycle arrest, genome instability, chromosomal breakage and senescence [155-158]. It has 
been hypothesized that the combination of genomic instability and subsequent somatic 
mutations allowing further irregular cellular proliferation can result in oncogenesis [159]. 
These valuable insights about importance of telomeres in biology of the cells became apparent 
after investigation on DC and the underlying genetic cause. 
Despite recent advances in the understanding of the genetic etiology of inherited BMF 
syndromes, in as many as about 40% of patients the underlying genetic cause remains 
unknown [160]. This work has shown that by the combination of next generation sequencing 
technology in association with basic biology investigations, new diseases can be identified 
and their molecular pathomechanisms can be understood. MYSM1 deficiency is characterized 
by a decreased capacity of cells to withstand genotoxic stresses, whereas SMARCD2 
deficiency is caused by defective chromatin remodeling machinery. Even though the 
observations reported in our papers do not yet provide direct cues for novel therapies for 
affected patients, our research is aimed towards the development of cures for patients with 
currently still incurable diseases. It is conceivable that drugs can be developed that 
specifically affect the function of MYSM1 or SMARCD2. At this point, the only curative 
approach for these patients consists in transplantation of AHSC – but this procedure remains 
associated with severe comorbidities and its effects are limited to the hematopoietic system. 
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